Page last updated: 2024-11-01

nialamide and Hepatic Encephalopathy

nialamide has been researched along with Hepatic Encephalopathy in 2 studies

Nialamide: An MAO inhibitor that is used as an antidepressive agent.

Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
ALBORNOZ-PLATA, A1
MAGNENAT, P1
OTT, T1
FREI, J1
DELALOYE, B1
KLAUS, E1

Other Studies

2 other studies available for nialamide and Hepatic Encephalopathy

ArticleYear
[Nialamide in gastroenterology. Its possible use in hepatic coma].
    Revista medica de Chile, 1961, Volume: 89

    Topics: Gastroenterology; Hepatic Encephalopathy; Humans; Iproniazid; Nialamide

1961
[Study of Niamid in hepatic encephalopathy].
    Chemotherapia, 1962, Volume: 4

    Topics: Hepatic Encephalopathy; Humans; Liver Cirrhosis; Monoamine Oxidase Inhibitors; Nialamide; Organic Ch

1962